New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review)

Abstract

Nuclear medicine is an essential part of prostate cancer management concerning initial staging, patient follow-up and even therapy. Prostate-specific membrane antigen (PSMA) is a glutamate carboxypeptidase II transmembrane glycoprotein expressed by 80% of prostatic cells. The interest in this protein is due to its specificity for prostatic tissue. The use of 68GaPSMA PET/CT in the context of disease staging is thus well-established and recommended, especially for high-risk disease with metastases and lymph node involvement. However, the risk of false positives raises questions regarding its place in the management of patients with prostate cancer. The present study aimed to determine the use of PET-PSMA in the care of patients with prostate cancer but also to assess its limits of use.

First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy

“…PSMA is a cell-surface protein over-expressed in the majority of prostate cancer cells and represents an ideal target to develop sensitive radio-active and fluorescent tracers [8][9][10]. The recent establishment of Gallium 68 PSMA-11 ligand PET-CT scanning has transformed the management of recurrent prostate cancer through the identification of small volume extra-prostatic disease and is being evaluated further for pre-operative staging and novel theranostics using labelling with the beta particle emitter Lutetium-177 ( 177 Lu) [11].…”